Anti-B7-1 Antibody

Price:
Size:
Number:

Anti-B7-1 Antibody (Rabbit Polyclonal antibody) General Information

Product name
Anti-B7-1 Antibody
Validated applications
ELISA
Species reactivity
Reacts with: Mouse
Specificity
Mouse B7-1
Immunogen
Recombinant Mouse CD80 / B7-1 protein (Catalog#50446-M08H)
Preparation
Produced in rabbits immunized with purified, recombinant Mouse CD80 / B7-1 (rM CD80 / B7-1; Catalog#50446-M08H; Q00609-1; Met 1-Lys 245). CD80 / B7-1 specific IgG was purified by Mouse CD80 / B7-1 affinity chromatography.
Source
Polyclonal Rabbit IgG
Purification
Protein A & Antigen Affinity
Formulation
0.2 μm filtered solution in PBS with 5% trehalose
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Anti-B7-1 Antibody (Rabbit Polyclonal antibody) Validated Applications

Application Dilution
ELISA 1:1000-1:2000
Please Note: Optimal concentrations/dilutions should be determined by the end user.

Anti-B7-1 Antibody: Alternative Names

Anti-B71 Antibody; Anti-Cd28l Antibody; Anti-Ly-53 Antibody; Anti-Ly53 Antibody; Anti-MIC17 Antibody; Anti-TSA1 Antibody

B7-1 Background Information

The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD8, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD8 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.
Full Name
CD80 molecule
References
  • Greenfield EA, et al. (1998) CD28/B7 costimulation: a review. Crit Rev Immunol. 18(5): 389-418.
  • Zang X, et al. (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13(18 Pt 1): 5271-9.
  • Mir MA, et al. (2008) Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets. 12(8): 969-79.
Add to Cart Successfully Add to Cart Failed